cilta-cel achieves deep and durable responses for r/r multiple myeloma
Published 3 years ago • 89 plays • Length 2:31Download video MP4
Download video MP3
Similar videos
-
4:33
cilta-cel elicits deep and durable responses in patients with multiple myeloma with early relapse
-
1:47
cilta-cel in earlier lines of therapy for r/r multiple myeloma
-
2:17
cilta-cel: a paradigm shift in the treatment of multiple myeloma
-
3:54
cilta-cel as a potential new soc for r/r multiple myeloma: insights from the cartitude-4 trial
-
1:17
efficacy & safety of standard of care cilta-cel in r/r multiple myeloma
-
4:04
the future of myeloma treatment and the possibility of cure
-
14:06
interpreting myeloma tests- case studies
-
9:25
mgus diagnosis: a step-by-step approach
-
2:53
novel targets and dual-targeting approaches in myeloma
-
3:02
real-world safety and efficacy of cilta-cel in r/r multiple myeloma
-
4:58
overview of the toxicities associated with bispecific agents in multiple myeloma
-
1:35
cilta-cel vs ide-cel for r/r multiple myeloma: making the decision in clinical practice
-
0:36
the recent expanded fda approval of cilta-cel and ide-cel into earlier lines of myeloma treatment
-
1:26
cilta-cel vs. therapies from real-world clinical practice for triple-class exposed myeloma
-
2:33
latest results from the cartitude-2 trial of cilta-cel in progressive multiple myeloma
-
0:50
car-t in multiple myeloma: cilta-cel & ide-cel
-
2:42
hdac8: a novel therapeutic target in multiple myeloma
-
1:28
real-world experience: ide-cel for r/r multiple myeloma
-
1:33
choosing between ide-cel and cilta-cel for the treatment of r/r multiple myeloma
-
3:54
highlights in multiple myeloma from ash 2021: cilta-cel, bispecific antibodies & disease biology
-
2:25
cartitude-5: vrd cilta-cel or rd in newly diagnosed multiple myeloma